Related Experiment Videos
Rivastigmine for Alzheimer's disease
J Birks1, Grimley Evans J, V Iakovidou
1Department of Clinical Geratology, University of Oxford, Oxford, UK, OX2 6HE. jacqueline.birks@geratology.ox.ac.uk
The Cochrane Database of Systematic Reviews
|October 18, 2000
Summary
Rivastigmine (a cholinesterase inhibitor) shows benefits for mild to moderate Alzheimer's disease, improving cognition and daily living. High doses (6-12mg) yielded significant results, though associated with more adverse events like nausea and vomiting.
Area of Science:
- Neuroscience
- Pharmacology
- Geriatrics
Background:
- Alzheimer's disease (AD) is a leading cause of dementia in the elderly.
- Cholinesterase inhibitors enhance cholinergic neurotransmission to manage AD symptoms.
- Rivastigmine offers an alternative to tacrine with improved safety and efficacy.
Purpose of the Study:
- To evaluate the clinical effectiveness and safety of rivastigmine in Alzheimer's disease patients.
- To compare rivastigmine's effects against placebo in treating dementia of the Alzheimer's type.
Main Methods:
- Systematic review of unconfounded, double-blind, randomized controlled trials.
- Inclusion criteria: Rivastigmine treatment >2 weeks for Alzheimer's dementia, placebo comparison.
- Data extraction and quality assessment performed by a single reviewer.
Main Results:
- Seven trials involving 3370 participants were analyzed.
- High-dose rivastigmine (6-12mg/day) significantly improved cognitive function (ADAS-Cog) and daily living (PDS) scores.
- Statistically significant increases in adverse events (nausea, vomiting, diarrhea) observed with high-dose rivastigmine.
Conclusions:
- Rivastigmine (6-12mg/day) demonstrates benefits in cognitive function, daily living, and dementia severity for mild to moderate AD.
- Adverse events are consistent with rivastigmine's cholinergic mechanism; further research on optimal dosing is recommended.
- The review did not include economic data.